On June 5, Appclon announced that the first patient dosing (FPI) has been completed for the global Phase 3 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results